Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • The future of RAS inhibitors

The future of RAS inhibitors

September 11, 2026Posted inBiotechnology

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.

Post navigation

Previous Post
FDA delays approval decision for Exelixis’ tyrosine kinase inhibitor in colorectal cancer
Next Post
New multi-scale fuzzy method enables unsupervised attribute reduction new-multi-scale-fuzzy-method-enables-unsupervised-attribute-reduction

Recent Posts

  • Iterative genetic programming builds feature subsets for high-dimensional classification
  • Joint entity and relation embedding advances multi-relational knowledge graph completion
  • Adaptive Chinese grammar teaching algorithm built with deep reinforcement learning
  • Post-discharge wearable mobility data predict readmission and mortality in metastatic cancer
  • DrowSFormer-XAI: explainable attention fusion network for driver drowsiness detection

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top